Thyroid cancer: A lethal endocrine neoplasm

Annals of Internal Medicine

Volumn 115, Issue 2, 1991, Pages 133-147

  Robbins, Jacob ^b   Merino, Maria J ^b   Boice Jr , John D ^b   Ron, Elaine ^b   Ain, Kenneth B ^a   Alexander, H Richard ^b   Norton, Jeffrey A ^b   Reynolds, James ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; IODINE 131; THYROGLOBULIN;

AGING; CONFERENCE PAPER; HISTOLOGY; HUMAN; METASTASIS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RADIATION; RISK FACTOR; THYROID CANCER; THYROID CARCINOMA;

CARCINOMA; CARCINOMA, PAPILLARY; HUMAN; NEOPLASMS, RADIATION-INDUCED; PROGNOSIS; THYROID NEOPLASMS;

EID: 0025864389     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-115-2-133     Document Type: Conference Paper

References (128)

1. Silverberg E, Boring CC, Squires TS. Cancer statistics, 1990. Ca. 1990;40:9-26.
2. Pickle LW, Mason TJ, Howard N, Hoover R, Fraumeni JF Jr. Atlas of U.S. Cancer Mortality among Whites: 1950-1980. Bethesda, Maryland: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health; 1987:DHHS Publication No. (NIH) 87-2900:177.
3. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer. 1989;63:908-11.
4. Hazard JB. Nomenclature of thyroid tumors. In: Inman DR, S. Young, eds. Thyroid Neoplasia. London: Academic Press; 1968:2-22.
5. Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Cleveland Clin Q. 1976;43:207-15.
6. Franssila KO. Value of histologic classification of thyroid cancer. Acta Pathol Micro Scand Suppl. 1981;225:5-76.
7. Livolsi VA, Merino MJ. Histopathologic differential diagnosis of the thyroid. Pathol Annu. 1981;16:357-406.
8. Tscholl-Ducommun J, Hedinger CE. Papillary thyroid carcinoma: morphology and prognosis. Virchows Arch [Pathol Anat]. 1982; 396:19-39.
9. Rosai J, Zampi G, Carcangiu ML. Papillary carcinoma of the thyroid: a discussion of its several morphologic expressions, with particular emphasis on the follicular variant. Am J Surg Pathol. 1983;7:809-17.
10. Vickery AL Jr, Carcangiu M, Johannessen JV, Sobrinho-Simoes M. Papillary carcinoma. Semin Diagn Pathol. 1985;2:90-100.
11. Carcangiu ML, Zampi G, Rosai J. Papillary thyroid cancer: a study of its many morphologic expresions and clinical correlates. Pathol Annu. 1985;20:1-44.
12. Hapke MR, Dehner LP. The optically clear nucleus: a reliable sign of papillary carcinoma of the thyroid? Am J Surg Pathol. 1979;3: 31-8.
13. Hoie J, Stenwig AE, Kullman G, Lindegaard M. Distant metastases in papillary thyroid cancer. A review of 91 patients. Cancer. 1988; 61:1-6.
14. Lindsay S. Carcinoma of the Thyroid Gland. Springfield, Illinois: Charles C. Thomas; 1960:43.
15. Franssila KO. Is the difference between papillary and follicular thyroid carcinoma valid? Cancer. 1983;32:853-64.
16. Chen KT, Rosai J. Follicular variant of thyroid papillary carcinoma: a clinicopathologic study of six cases. Am J Surg Pathol. 1977;1:123-30.
17. Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol. 1987;14:315-32.
18. Simpson WJ, McKinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe SB, Panzarella T. Papillary and follicular cancer: prognostic factors in 1,578 patients. Am J Med. 1987;83:479-88.
19. Kahn NF, Perzin KH. Follicular carcinoma of the thyroid: an evaluation of the histologic criteria used for diagnosis. Pathology Annual Monograph; 1983; Part I, 14:221-53.
20. Merino MJ, Kennedy S, Norton JA, Robbins J. Pleural involvement by metastastic thyroid carcinoma "tall cell variant": an unusual occurrence. Surg Pathol. 1990;3:59-64.
21. Johnson TL, Lloyd RV, Thompson NW, Beierwaltes WH, Sisson JC. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol. 1988;12:22-7.
22. Thompson NW, Dunn EL, Batsakis JG, Nishiyama RH. Hurthle cell lesions of the thyroid gland. Surg Gynecol Obstect. 1984;139:555-60.
23. Bronner MP, LiVolsi VA. Oxyphilic (Askanazy/Hurthle cell) tumors of the thyroid. Microscopic features predict biologic behavior. Surg Pathol. 1988;1:137-50.
24. Evans HL. Columnar-cell carcinoma of the thyroid: a report of two cases of an aggressive variant of thyroid carcinoma. Am J Clin Pathol. 1986;85:77-80.
25. Sobrinho-Simoes MA, Nesland JM, Johannessen JV. Columnar-cell carcinoma: another variant of poorly differentiated carcinoma of thyroid. Am J Clin Pathol. 1988;89:264-7.
26. Vickery AL Jr. Thyroid papillary carcinoma. Pathological and philosophical controversies. Am J Surg Pathol. 1983;7:797-807.
27. LiVolsi VA. Surgical pathology of the thyroid. In: Bennington JL, ed. Major Problems in Pathology. Philadelphia: W.B. Saunders; 1990:386-91.
28. Pottern LM, Stone BJ, Day NE, Pickle LW, Fraumeni JF Jr. Thyroid cancer in Connecticut, 1935-1975: an analysis by cell type. Am J Epidemiol. 1980;112:764-74.
29. Crile G Jr, Esselstyn CB Jr, Hawk WA. Needle biopsy in the diagnosis of thyroid nodules appearing after radiation [Editorial]. N Engl J Med. 1979;301:997-9.
30. Prentice RL, Kato H, Yoshimoto K, et al. Radiation exposure and thyroid cancer incidence among Hiroshima and Nagasaki residents. Natl Cancer Inst Monogr. 1982;62:207-12.
31. Ezaki H, Ishimaru T, Hayashi Y, Takeichi N. Cancer of the thyroid and salivary glands. In: Shigematsu I. Kagan A, eds. Cancer in Atomic Bomb Survivors. Gann Monograph on Cancer Research No. 32. New York: Plenum Press; 1986:129-42.
32. Shore RE, Woodward E, Hildreth N, Dvoretsky P, Hempelmann L, Pasternack B. Thyroid tumors following thymus irradiation. J Natl Cancer Inst. 1985;74:1177-84.
33. Schneider AB, Shore-Freedman E, Ryo UY, Bekerman C, Favus M, Pinsky S. Radiation-induced tumors of the head and neck following childhood irradiation. Prospective studies. Medicine (Baltimore). 1985;64:1-15.
34. Fürst CJ, Lundell M, Holm LE, Silfversward C. Cancer incidence after radiotherapy for skin hemangioma. A retrospective cohort study in Sweden. J Natl Cancer Inst. 1988;80:1387-92.
35. Ron E, Modan B, Preston D, Alfandary E, Stovall M, Boice JD Jr. Thyroid neoplasia following low-dose radiation in childhood. Radiat Res. 1989;120:516-31.
36. Pottern LM, Kaplan MM, Larsen PR, et al. Thyroid nodularity after childhood irradiation for lymphoid hyperplasia. A comparison of questionnaire and clinical findings. J Clin Epidemiol. 1990;43: 449-60.
37. Tucker MA, Meadows AT, Morris-Jones P, et al. Therapeutic radiation at young age linked to secondary thyroid cancer. Proc Am Soc Clin Oncol. 1986;5:211.
38. de Vathaire F, Francois P, Schweisguth O, Oberlin O, Le MG. Irradiated neuroblastoma in childhood as potential risk factor for subsequent thyroid tumor [Letter]. Lancet. 1988;2:455.
39. Boice JD Jr, Engholm G, Kleinerman RA, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res. 1988;116:3-55.
40. Dobyns BM, Sheline GE, Workman JB, Thompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism. A report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab. 1984;38:976-98.
41. Holm LE, Hall P, Wiklund KE, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. 1991;[In press].
42. Holm LE, Wiklund KE, Lundell GE, et al. Thyroid cancer after diagnostic doses of iodine-131. A retrospective cohort study. J Natl Cancer Inst. 1988;80:1132-8.
43. Conard RA. Late radiation effects in Marshall Islanders exposed to fallout twenty-eight years ago. In: Boice JD Jr. Fraumeni JF Jr, eds. Radiation Carcinogenesis, Epidemiology and Biological Significance. New York: Raven Press; 1984:57-71.
44. Hamilton TE, van Belle G, LoGerfo JP. Thyroid neoplasia in Marshall Islanders exposed to nuclear fallout. JAMA. 1987;258:629-35.
45. Rallison ML, Dobyns BM, Keating FR Jr, Rall JE, Tyler FH. Thyroid nodularity in children. JAMA. 1975;233:1069-72.
46. Wang ZY, Boice JD Jr, Wei LX, et al. Thyroid nodularity and chromosome aberrations among women in areas of high background radiation in China. J Natl Cancer Inst. 1990;82:478-85.
47. Hempelmann LH. Risk of thyroid neoplasms after irradiation in childhood. Science 1968;160:159-63.
48. Ron E, Kleinerman RA, Boice JD Jr, LiVolski VA, Flannery JT, Fraumeni JF Jr. A population-based case-control study of thyroid cancer. J Natl Cancer Inst. 1987;79:1-12.
49. National Council on Radiation Protection and Measurements. Influence of Dose and Its Distribution in Time on Dose-Response Relationships for Low-LET Radiations. Washington, DC: National Council on Radiation Protection and Measurements; 1980:report no. 64.
50. Anspaugh LR, Catlin RJ, Goldman M. The global impact of the Chernobyl reactor accident. Science. 1988;242:1513-9.
51. Mortensen JD, Bennett WA, Woolner LB. Incidence of carcinoma in thyroid glands removed at 1000 consecutive routine necropsies. Surg Forum. 1954;5:659-63.
52. DeGroot LJ, Reilly M, Pinnameneni K, Refetoff S. Retrospective and prospective study of radiation-induced thyroid disease. Am J Med. 1983;74:852-62.
53. Gharib H, James EM, Charboneau JW, Naessens JM, Offord KP, German CA. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study. N Engl J Med. 1987;317:70-5.
54. Gharib H, Goellner JR, Zinsmeister AR, Grant CS, van Heerden JA. Fine-needle aspiration biopsy of the thyroid: the problem of suspicious cytologic findings. Ann Intern Med. 1984;101:25-8.
55. Hamburger JI. Consistency of sequential needle biopsy findings for thyroid nodules. Arch Intern Med. 1987;147:97-9.
56. Simpson WJ, McKinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe SB, Panzarella T. Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. Am J Med. 1987;83:479-88.
57. Schelfhout LJ, Creutzberg CL, Hamming JF, et al. Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. Eur J Cancer Clin Oncol. 1988;24: 331-7.
58. Nel CJ, van Heerden JA, Goellner JR, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc. 1985;60:51-8.
59. Rosai J, Saxen EA, Woolner L. Undifferentiated and poorly differentiated carcinoma. Semin Diagn Pathol. 1985;2:123-36.
60. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1986;61:978-96.
61. Lang W, Choritz H, Hundeshagen H. Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol. 1986;10:246-55.
62. Rossi RL, Cady B, Silverman ML, et al. Surgically incurable well-differentiated thyroid carcinoma. Prognostic factors and results of therapy. Arch Surg. 1988;123:569-74.
63. Cady B, Rossi R, Silverman M, Wool M. Further evidence of the validity of risk group definition in differentiated thyroid carcinoma. Surgery. 1985;98:1171-8.
64. 131I therapy in differentiated thyroid carcinoma: M. D. Anderson Hospital experience. Cancer. 1981;47:664-71.
65. Tubiana M, Schlumberger M, Rougier P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 1985;55:794-804.
66. Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol. 1987;14:315-32.
67. Hoie J, Stenwig AE, Kullman G, Lindegaard M. Distant metastases in papillary thyroid cancer. A review of 91 patients. Cancer. 1988; 61:1-6.
68. Pochin EE. Radioiodine therapy of thyroid cancer. Semin Nucl Med. 1971;1:503-15.
69. Waxman A, Ramanna L, Chapman N, et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med. 1981;22:861-5.
70. Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxford). 1985; 23:405-11.
71. Pacini F, Ceccarelli C, Elisei R, Grasso L, Pinchera A. Serum thyroglobulin determination in thyroid cancer. A ten years experience. In: Nagataki S, Torizuka K, eds. The Thyroid 1988. Amsterdam: Elsevier Science Publishers; 1988:685-9.
72. Clark OH, Levin K, Zeng QH, Greenspan FS, Siperstein A. Thyroid cancer: the case for total thyroidectomy. Eur J Cancer Clin Oncol. 1988;24:305-13.
73. Niederle B, Roka R, Schemper M, Fritsch A, Weissel M, Ramach W. Surgical treatment of distant metastases in differentiated thyroid cancer: indication and results. Surgery. 1986;100:1088-97.
74. DeGroot LJ, Reilly M. Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med. 1982;96:51-3.
75. Ramacciotti C, Pretorias HT, Line BR, Goldman JM, Robbins J. Ablation of nonmalignant thyroid remnants with low doses of radioactive iodine: concise communication. J Nucl Med. 1982;23: 483-9.
76. Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of "ablation of thyroid remnants" with 1-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med. 1984;25:1287-93.
77. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937-41.
78. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol. 1986;59:45-51.
79. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radiat Ther Nucl Med. 1962;87:171-82.
80. Varma VM, Beierwaltes WH, Nofal MM, Nishiyama RH, Copp JE. Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodide I-131. JAMA. 1970;214:1437-42.
81. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer. 1987;60:2372-5.
82. Ahuja S, Ernest H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest. 1987;10:303-10.
83. Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab. 1959;19:152-61.
84. Mathew CG, Chiu KS, Easton DF, et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature. 1987;328:527-8.
85. Simpson NE, Kidd KK, Goodfellow PJ, et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature. 1987;328:528-30.
86. Norton JA, Froome LJ, Farell RE, Wells SA Jr. Multiple endocrine neoplasia type IIb: the most aggressive form of medullary thyroid cancer. Surg Clin North Am. 1979;59:109-18.
87. Rossi L, Cady B, Meissner WA, Wool MS, Sedgwick CE, Werber J. Nonfamilial medullary thyroid carcinoma. Am J Surg. 1980;139:54-60.
88. Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab. 1988;67:801-5.
89. Cance WB, Wells SA Jr. Multiple endocrine neoplasia. Type IIa. Curr Probl Surg. 1985;22:1-56.
90. Williams ED. Diarrhea and thyroid cancer. Proc R Soc Med. 1966;59:602-3.
91. Wells SA Jr, Dilley WG, Farndon JA, Leight GS, Baylin SB. Early diagnosis and treatment of medullary thyroid carcinoma. Arch Intern Med. 1985;145:1248-52.
92. Tippins JR, Morris HR, Panico M, et al. The myotropic and plasma-calcium modulating effects of calcitonin gene-related peptide (CGRP). Neuropeptides. 1984;4:425-34.
93. Lippman SM, Mendelsohn G, Trump DL, Wells SA Jr, Baylin SB. The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase. J Clin Endocrinol Metab. 1982;54: 233-40.
94. Busnardo B, Girello ME, Simione N, Nacamulli D, Busetto E. Non-parallel patterns of calcitonin and carcinoembryonic antigen level in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53: 278-85.
95. Wells SA Jr, Baylin SB, Leight GS, Dale JK, Dilley WG, Farndon Jr. The importance of diagnosis in patients with hereditary medullary thyroid carcinoma. Ann Surg. 1982;195:595-9.
96. Telander RL, Zimmerman D, Sizemore GW, van Heerden JA, Grant LS. Medullary thyroid carcinoma in children: results of early detection and diagnosis. Arch Surg. 1989;124:841-3.
97. Gautvik KM, Talle K, Hafer B, Jorgensen OG, Aas M. Early liver metastases in patients with medullary carcinoma of the thyroid gland. Cancer. 1989;63:175-80.
98. Norton JA, Doppman JL, Brennan MF. Localization and resection of clinically inapparent medullary carcinoma of the thyroid. Surgery. 1980;87:616-22.
99. Tisell LE, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 1986;90:60-6.
100. Nelkin BD, de Bustros AC, Mabry M, Baylin SB. The molecular biology of medullary thyroid carcinoma: a model for cancer development and progression. JAMA. 1989;261:3130-5.
101. Shimaoka K, Schoenfeld DA, DeWys W, Creich RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56: 2155-60.
102. Petursson SR. Metastatic medullary thyroid carcinoma: complete response to combination chemotherapy with decarbazine and 5-fluorouracil. Cancer. 1988;62:1899-903.
103. Schroder S, Bocker W, Baisch H, et al. Prognostic factors in medullary thyroid carcinomas: survival in relation to age, sex, stage, history, immunochemistry and DNA content. Cancer. 1988; 61:806-16.
104. Duh QY, Sancho JJ, Greenspan FS, et al. Medullary thyroid carcinoma: the need for early diagnosis and total thyroidectomy. Arch Surg. 1989;124:1206-10.
105. 131I. In: Medeiros-Neto GA. Gaitan E, eds. Frontiers in Thyroidology. New York: Plenum Medical; 1986:1317-21.
106. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkins lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989;7:1027-38.
107. Movius EG, Robbins J, Pierce LR, et al. The value of lithium in radioiodine therapy of thyroid carcinoma. In: Medeiros-Neto GA, Gaitan E, eds. Frontiers in Thyroidology. New York: Plenum Medical; 1986:1269-72.
108. Robbins J. The role of TRH and lithium in the management of thyroid cancer. In: Robbins J, Andreoli M, Monaco F, eds. Advances in Thyroid Neoplasia. Rome: Field Educational Italia; 1981:233-44.
109. Pons F, Carrio I, Estorch M, Ginjaume M, Pons J, Milian R. Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin Nucl Med. 1987; 12:644-7.
110. Kelland LR, Steel GG. Inhibition of recovery from damage induced by ionizing radiation in mammalian cells. Radiother Oncol. 1988; 13:285-99.
111. Fitzgerald PF, Foote FW, Hill RF. Concentration of I-131 in thyroid cancer shown by radioautography. Cancer. 1950;3:86-105.
112. Adelstein SJ, Rassis AI. Radiobiologic implications of the microscopic distribution of energy from radionuclides. Int J Rad Appl Instrum [B]. 1987;14:165-9.
113. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med. 1986;27:1490-7.
114. Arnstein NB, Carey JE, Spaulding SA, Sissons JC. Determination of iodine-131 diagnostic dose for imaging metastatic thyroid cancer. J Nucl Med. 1986;27:1764-9.
115. Brown I. Astatine-211: its possible applications in cancer therapy. Int J Radiat Appl Instrum [A]. 1986;37:789-98.
116. Cobb LM, Harrison A, Dudley NE, Carr TE, Humphreys JA. Relative concentration of astatine-211 and iodine-125 by human fetal thyroid and carcinoma of the thyroid in nude mice. Radiother Oncol. 1988;13:203-9.
117. Cobb LM, Harrison A, Butler SA. Toxicity of astatine-211 in the mouse. Hum Toxicol. 1988;7:529-34.
118. Stanta G, Carcangiu ML, Rosai J. The biochemical and immunohistochemical profile of thyroid neoplasia. Pathol Annu. 1988;23: 129-57.
119. Harach JR, Franssila KO. Thyroglobulin immunostaining in follicular thyroid carcinoma: relationship to the degree of differentiation and cell type. Histopathology. 1988;13:43-54.
120. Fairweather DS, Bradwell AR, Watson-James SF, Dykes PW, Chandler S, Hoffenberg R. Detection of thyroid tumors using radiolabelled anti-thyroglobulin. Clin Endocrinol (Oxford). 1983;18:536-70.
121. 123I anti-human thyroglobulin antibody. Eur J Nucl Med. 1985;10:291-5.
122. Kusakabe K, Mori E, Kano K, Ohta Y, Fujimoto Y, Mori T. Production of monoclonal antibody to thyroglobulin from malignant thyroid carcinoma. Jpn J Exp Med. 1989;59:37-42.
123. Schroder S, Muller-Gartner HW, Schrolff R, Schmiegelow P, Niendorf A, Bocker W. Morphological demonstration and quantification of TSH binding sites in neoplastic and non-neoplastic thyroid tissues. Virchows Arch [A]. 1986;409:555-70.
124. Edmonds CJ, Kermode JC. Thyrotrophin receptors, tumour radioiodine concentration and thyroglobulin secretion in differentiated thyroid cancers. Br J Cancer. 1985;52:537-41.
125. Liaw KY, Chang-Chien Y, Chen YC, Deng JS. Imparied cell-mediated immunity function in thyroid cancer. Cancer. 1980;46: 285-8.
126. Lo Gerfo P, Feind C, Weber C, Ting W. Immunotherapy of thyroid cancer by induction of autoimmune thyroiditis. Surgery. 1983;94: 959-65.
127. Rosenberg SA, Longo DL, Lotze MT. Principles and applications of biologic therapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Philadelphia: J.B. Lippincott; 1989:301-47.
128. Atkins MB, Mier JW, Parkinson DR, Could JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988;318: 1557-63.